The clinical response to omalizumab in chronic spontaneous urticaria patients is linked to and predicted by IgE levels and their change

In CSU, total IgE levels and their change predict the response to treatment with omalizumab. The assessment of pre- and post-treatment IgE levels and their ratio may help to improve the management of CSU in patients who require omalizumab treatment.